this picking a Mfg is odd at this stage in the game. no details of what this would mean as far as how much this is going to cost. This company is a "Contract MFG". This move would be more inline at a later time. The Stage 2 Trials is for the most part is on formulating the drug and then having that go thru a wider human sample set than what was done in Stage 1. you are trying to figure out what dosage levels work and then kind of pick the "Sweet Spot". Its all about the uptake of the drug in the humans and then uping the dosages or lowering them. And from all research I have done so far, this ends up being by far the most costly of the stages of any drug research.
I've been trying to understand a little more on how various drug related companies go thru these Trials and Processes.
So far it is a little strange that all these people coming on board are all from the one company that has been doing the initial research. And what this kind of smells like is they are using JAN as a means to raise money via the Stock Market where they could not do this via their existing entity without going thru all the basic requirements to sell stock to the public. Finance People tend to call this a "Poorman's IPO".
ARCI is then Pumping up the Stock on all these PR Moves.
Then there is GEOTRAQ hanging onto JAN/ARIC like a Dead Weight burning thru their Working Capital with NO Sales.
When are they going to announce that it is time to "Cut Bait" on Geotraq?
News 
Market Data 
Discover 
